Company: LNAI
Filing Date: 2025-12-03
Form Type: 424B5
Source: 0001731122-25-001626
Chunk: 39

Company: Lunai Bioworks Inc.
Filing Date: 2025-12-03
Form: 424B5
Chunk 39
---
 documents which are incorporated by reference
into this prospectus, as well as the risk factors and other information contained in or incorporated by reference into any accompanying
prospectus supplement before investing in any of our securities. Our business, financial condition, results of operations, cash flows
or prospects could be materially and adversely affected by any of these risks. The risks and uncertainties described in the documents
incorporated by reference herein are not the only risks and uncertainties that you may face.

For more information about our
SEC filings, please see the sections entitled “Where You Can Find More Information” and “Incorporation of Certain Documents
by Reference” below.

<div align='center'>USE OF PROCEEDS</div>

We will retain broad discretion
over the use of the net proceeds from the sale of the securities offered hereby. Unless otherwise specified in a prospectus supplement
accompanying this prospectus, the net proceeds from the sale by us of the securities to which this prospectus relates will be used for
working capital and general corporate purposes. Our expected use of proceeds from the sale of the securities offered hereby represents
our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty
all of the particular uses for the proceeds to be received from the sale of the securities offered hereby or the amounts that we will
actually spend on the uses set forth above.

When we offer and sell the securities
to which this prospectus relates, the prospectus supplement related to such offering will set forth our intended use of the proceeds,
if any, received from the sale of such securities.

<div align='center'>5

DESCRIPTION OF CAPITAL STOCK</div>

General

The following description of our
capital stock, together with any additional information we include in any applicable prospectus supplement or any related free writing
prospectus, summarizes the material terms and provisions of our common stock that we may offer under this prospectus. For the complete
terms of our common stock, please refer to our articles of incorporation and our bylaws that are incorporated by reference into the registration
statement of which this prospectus is a part. The summary below and that contained in any applicable prospectus supplement or any related
free writing prospectus are qualified in their entirety by reference to our articles of incorporation and our bylaws.

Common Stock

We are authorized to issue 350,000,000 shares of common stock, $0.0001 par
value per share. As of October